Soc. Generale Call 185 ABBV 21.06.../ DE000SQ3S3H8 /
| 5/29/2024 4:40:25 PM | Chg.0.000 | Bid4:40:31 PM | Ask4:40:31 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.001EUR | 0.00% | 0.001 Bid Size: 125,000 |
0.028 Ask Size: 125,000 |
AbbVie Inc | 185.00 USD | 6/21/2024 | Call |
GlobeNewswire
5/28
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Imp...
GlobeNewswire
5/28
CEREVEL THERAPEUTICS ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: C...
GlobeNewswire
5/28
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
GlobeNewswire
5/25
CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law ...
GlobeNewswire
5/24
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7...
GlobeNewswire
5/23
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire
5/22
Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physic...
GlobeNewswire
5/22
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
5/22
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
5/22
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...
GlobeNewswire
5/21
BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by Ab...
GlobeNewswire
5/21
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire
5/17
INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerev...
GlobeNewswire
5/16
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
GlobeNewswire
5/14
CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough...
GlobeNewswire
5/14
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
GlobeNewswire
5/14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
